Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG develops DARPin therapeutics, a class of custom-built protein drugs used in oncology-focused drug development. Company updates center on its clinical-stage and preclinical pipeline, including Radio-DARPin candidates for targeted radiopharmaceuticals, tumor-localized immune activation programs, and next-generation immune cell engagers for cancer.
Recurring developments include scientific conference presentations, peer-reviewed clinical data, preclinical research, partnership activity, annual financial results, and shareholder-meeting governance. Key program references include MP0712, a DLL3-targeting Radio-DARPin for small cell lung cancer and other DLL3-expressing neuroendocrine cancers; MP0317, a FAPxCD40 DARPin designed for tumor-localized CD40 activation; and Switch-DARPin and T cell engager candidates for solid tumors and hematologic cancers.
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a biotech firm specializing in DARPin® therapeutics, announced that CEO Patrick Amstutz will present at two virtual healthcare investor events in September 2021. The first event is the Morgan Stanley 19th Annual Global Healthcare Conference on September 10 at 11:00 AM ET. The second is the H.C. Wainwright 23rd Annual Global Investment Conference, happening from September 13-15, with presentations available on demand from September 13 at 7:00 AM ET. Webcasted presentations will be accessible on the company's website.
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) announced significant advancements in its COVID-19 therapeutic trials, particularly its lead candidate ensovibep. Two late-stage trials, EMPATHY and ACTIV-3, have been initiated with positive interim data expected in the second half of 2021. The FDA awarded Fast Track designation for ensovibep, which maintains efficacy against SARS-CoV-2 variants. Financial results for H1 2021 showed revenues of CHF 4.4 million, but the firm reported an operating loss of CHF 34.8 million, reflecting rising expenses and ongoing cash utilization. Cash reserves stand at CHF 174.3 million, supporting operations until H2 2023.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced the return of global rights to its investigational drug abicipar pegol from AbbVie due to the termination of their collaboration agreement. This drug targets neovascular age-related macular degeneration (nAMD) and Diabetic Macular Edema (DME). Molecular Partners has made improvements in the drug's manufacturing and formulation to potentially reduce inflammatory side effects. The company plans to evaluate next steps for abicipar while continuing its discovery alliance with AbbVie for other ophthalmic therapies.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) reports progress on its antiviral candidate, ensovibep, designed to combat SARS-CoV-2. It retains full potency against all known variants, including Delta. The EMPATHY Phase 2/3 trial is enrolling patients across 5 countries, with expansion planned. The ACTIV-3 trial for hospitalized patients is actively recruiting. A subcutaneous formulation is set for clinical trials in H2 2021. Ensovibep shows potential for differentiated treatment amid mixed vaccination rates globally.